scholarly journals Factors associated with cumulative research funding of investigators from CIHR – a major health-research funding agency

2011 ◽  
Vol 34 (4) ◽  
pp. 217
Author(s):  
Malathi Raghavan
Keyword(s):  
Health Research ◽  
Research Funding ◽  
Academic Research ◽  
Positive Association ◽  
Median Number ◽  
Research Area ◽  
Funding Agency ◽  
P Value ◽  
Award Recipient ◽  
Number Of Publications

Purpose: Few systematic studies have focused on determinants of cumulative research funding (CRF), a measure of research productivity among career researchers world-wide. Using researchers funded by the Canadian Institutes for Health Research (CIHR), this exploratory study quantifies the association between CIHR-investigator roles and CRF obtained from the CIHR. Methods: CIHR grants and awards obtained in fiscal years 1999-2006 by non-trainee principal investigators (PI) and by supervisors of CIHR trainee awards were used to determine investigator-level CRF. Log-transformed CRF was regressed on investigator role as CIHR-salary award recipient or supervisor of CIHR-trainee award recipients after adjustment for number of project-years, research area, and PI status. Number of publications in life sciences and biomedical journals from January 2000 to August 2007 was compared among 80 randomly-selected CIHR-investigators who were supervisors (n=40) and non-supervisors (n=40). Reported results were considered significant at P-value < 0.05. Results: Multiple regression analysis based on 6515 CIHR-investigators indicated that salary award recipients were associated with a 29.5% higher CRF but the magnitude of this positive association was inversely associated with time since first receiving salary award. Supervisors were associated with, on average, a 13.1% decrease in CRF; increasing numbers of trainees supervised was associated with decreasing CRF. Earlier recipients of grants and salary awards were more likely also supervisors. The median number of publications for supervisors was higher than that for non-supervisors (31 vs. 11.5). Conclusions: Demonstrated associations between investigator-level CRF and predictors suggest that CRF should be considered in the context of investigators’ multiple roles. The study, without establishing causality, also documents evidence of multi-lateral returns to the enterprise of academic research from salary and trainee awards. The major limitation is that CRF and predictors are derived from a single funding agency. Findings should be viewed as preliminary and should serve to develop hypotheses for future, comprehensive research.

scholarly journals Characteristics and Outcome of Adults with Severe Autoimmune Hemolytic Anemia Admitted in Intensive Care Unit: Results from a Large French Observational Study

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 930-930
Author(s):  
Clara Pouchelon ◽  
Charlotte Lafont ◽  
Antoine Lafarge ◽  
Thibault Comont ◽  
Etienne Riviere ◽  
...  
Keyword(s):  
Mortality Rate ◽  
Bilirubin Level ◽  
Research Funding ◽  
Median Number ◽  
P Value ◽  
Inclusion Criteria ◽  
Baseline Characteristics ◽  
High Bilirubin ◽  
Overall Mortality

Abstract Introduction : Adult' autoimmune hemolytic anemia (AIHA) can be life-threatening with an overall mortality rate of 8-10% which can rise up to 30% for patients admitted in intensive care unit (ICU). The factors associated with the need of management in ICU are partially unknown as only few data are available in the literature. To better describe the baseline characteristics and outcome of severe adult'AIHA admitted in ICU and to identify some prognostic factors, an observational multicentre study was set up by the French reference center of adult' immune cytopenias. Patients and Methods : This was an observational retrospective multicentre study. Patients had to fulfill the following inclusion criteria : 1) Age ≥ 18 years at time of AIHA onset ; 2) Definite diagnosis of primary or secondary warm (wAIHA), cold (cAIHA) or mixed AIHA ; 3) At least one admission in ICU specifically for the management of AIHA. Patients with AIHA admitted in ICU for another reason than the severity of AIHA were excluded. Patients' baseline characteristics at time of admission in ICU were recorded by means of a standardized form including the Charlson comorbidity score, the Knaus score, the Sequential Organ Failure Assessment (SOFA) and the Simplified Acute Physiology Score (SAPS II). Categorical variables were expressed as number (percentage) and quantitative variable as median [interquartile range]. To identify factors associated with death in ICU or after 1 year of follow-up, patients' characteristics were compared using usual tests. In order to identify some parameters associated with the risk of admission in ICU, the main characteristics of the patients were compared to those of controls (1 to 2 ratio) diagnosed with AIHA and followed over the same period who were never admitted in ICU. Univariate logistic regressions analyses were performed followed by a multivariate logistic regression using a backward stepwise selection procedure. A p-value &lt;0.05 was considered as statistically significant. Results : In total, 62 patients (42% of females) from 11 centers fulfilling the inclusion criteria were included for a total of 69 admissions in ICU (see table for baseline characteristics). Of note, 57/62 patients (92%) had a low (&lt; 121) bone marrow reticulocytes index (BMRI) reflecting an impaired erythropoiesis. The mortality rate in ICU was 13%; 3 patients died from massive pulmonary embolism. Compared to the 54 survivors the 8 patients who died in ICU had: a higher CRP level (p value = 0.011); a higher need for transfusion (median number of packed red cells was 12 versus 4, p value = 0.008); higher SOFA and IGS scores (p value = 0.006); a higher number of organ failures on admission (p value &lt; 0.001), thrombotic events (p value = 0.024) and sepsis during the stay in ICU (p value = 0.019). Among the survivors, 9/49 (5 lost of follow-up) eventually died within a year after the admission in ICU leading to an overall mortality rate of 30% at 1 year. For the management of AIHA in ICU, 56 patients (90%) were transfused (median number of packed red cells = 4 [2-7]); recombinant Epo was administered to 14 patients (22.5%) and 5 patients (8%) had plasma exchange. In ICU, 58 patients (95%) were treated with corticosteroids, 29 (46%) received at least one other treatment line including mostly : rituximab (n = 22), intravenous immunoglobulin (n = 10), iv cyclophosphamide (n = 5), cyclosporin (n = 3). Other treatment lines including chemotherapy-based regimen (n=8) were given afterwards. The characteristics of the 62 patients were compared to those of 138 controls with AIHA who were never admitted in ICU. In univariate analyses, younger age, Evans' syndrome, Hb level &lt; 6 g/dl; reticulocytes count &lt; 100 x 10 9/L, BMRI &lt;121 and high bilirubin level were significantly associated with an admission in ICU. In multivariate analysis, a low Hb level and a high bilirubin level were the only parameters that were significantly associated with the risk of admission in ICU Conclusion : Based on this retrospective study, the mortality rate of adult patients admitted in ICU for AIHA was lower than expected (13%) but the 1 year mortality rate in this population of patients rose up to 30%. Patients with AIHA and a Hb level &lt; 6g/dl, a high bilirubin level and/or an inadequate reticulocytes count must be treated promptly and monitored closely beyond the initial phase of the disease in order to reduce the mortality rate. The treatment of severe refractory cases is not consensual and should be harmonized. Figure 1 Figure 1. Disclosures Comont: Takeda: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding. Riviere: Octapharma: Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees. Haioun: Janssen: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; F. Hoffmann-La Roche Ltd: Honoraria, Research Funding; Servier: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Miltenyi: Honoraria, Research Funding. Godeau: Amgen: Consultancy; Sobi: Consultancy; Novartis: Consultancy; Grifols: Consultancy. Michel: Amgen: Consultancy; Rigel: Honoraria; Alexion: Honoraria; UCB: Honoraria; Argenx: Honoraria; Novartis: Consultancy. OffLabel Disclosure: rituximab is commonly used off-label as a second line for adult' AIHA

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. LBA-5-LBA-5 ◽  
Author(s):  
Andrew D Zelenetz ◽  
Tadeusz Robak ◽  
Bertrand Coiffier ◽  
Julio Delgado ◽  
Paula Marlton ◽  
...  
Keyword(s):  
High Risk ◽  
Research Funding ◽  
Median Number ◽  
Hazard Ratio ◽  
Controlled Study ◽  
Forest Plot ◽  
P Value ◽  
Employment Equity ◽  
Prior Therapy ◽  
Equity Ownership

Abstract Introduction: Idelalisib (IDELA) is a 1st-in-class targeted PI3k delta inhibitor approved in combination with rituximab for the treatment of patients (pts) with relapsed CLL and as first-line treatment where 17p deletion or TP53 mutation exists in pts unsuitable for chemo-immunotherapy. Here, we present the results of a phase III, randomized, placebo-controlled study that evaluated the efficacy of IDELA added to BR, a common regimen for relapsed/refractory (R/R) CLL. A pre-specified interim analysis (IA) was performed demonstrating that PFS, the primary endpoint, and OS, a secondary endpoint, were superior in the investigational vs control arm. The IDMC recommended unblinding the study based on “overwhelming efficacy.” Methods: Between June 2012 and August 2014, 416 patients (pts) with R/R CLL were enrolled. The IA occurred when 75% of the total number of 260 planned events of CLL progression or death from any cause had occurred with a data cutoff of 15 June 2015. Key eligibility requirements included prior therapy containing a purine analog or bendamustine (ineligible if refractory to bendamustine); prior treatment with an anti-CD20 antibody; CLL progression within 36 months of the completion of the last prior therapy; and fitness to receive cytotoxic therapy. Patients were randomized to BR for 6 cycles Q 28 days (B = 70 mg/m2 D1, D2 of each cycle; R = 375 mg/m2 C1 and 500 mg/m2 C2-6) and IDELA 150 mg BID or placebo (administered continuously). Treatment with IDELA or placebo was administered until IRC-confirmed disease progression (PD), death, intolerable toxicity, or withdrawal of consent. Stratification was based on presence/absence of del(17p) and/or p53 mutation (mut), immunoglobulin heavy chain variable region (IGHV) mutated/unmutated (analysis performed by a central lab) and disease status refractory (CLL progression <6 months from completion of prior therapy) vs relapsed (CLL progression ≥ 6 months from completion of prior therapy). Imaging by CT was performed every 12 weeks and evaluated by an independent review committee (IRC) for evidence of PD. Crossover was not permitted at the time of PD. Results: The ITT analysis includes 207 pts in the IDELA + BR arm and 209 pts in the BR + placebo arm: gender 76% male; age 58%/42% (<65yrs/≥65 years); Rai stage III/IV 46%; median time since completion of last prior therapy 16 months; patients with high-risk features (del(17p)/p53mut 32.9%, unmutated IGHV 83.2%, refractory 29.8%); median number of prior therapies: 2 (range: 1-13); and median follow up 12 months. Median number of cycles of BR completed in the two arms was equal (6). Median PFS (mo) of IDELA + BR vs BR + placebo: 23 vs 11 (hazard ratio 0.33; p-value 2.8 x 10-14; 95% CI 0.24, 0.45) (Fig 1), corresponding HRs in pts with high-risk features (Fig 2); mOS (mo): IDELA + BR vs BR + placebo not reached for either arm (HR = 0.55; p-value 0.008; 95% CI 0.36, 0.86). The most common all-grade AEs with IDELA + BR were neutropenia and pyrexia (63.3% vs 41.5%), and with BR + placebo were neutropenia and nausea (53.6% vs 34.4%). The most common grades ≥3 AEs respectively were neutropenia (59.9%) and febrile neutropenia (20.3%); neutropenia (45.9%) and anemia (12%). Grade ≥3 diarrhea with IDELA + BR was 7.2% and BR + placebo was 1.9%. Incidence of SAE pneumonitis was 1.4% vs 0%. Transaminase abnormalities were observed more frequently in the IDELA + BR vs BR + placebo arm: all grades ALT 59.9%/30.6%, AST 52.2%/27.8%, Grade ≥3 ALT 21.3%/2.9%, AST 15.5%/3.3%. Figure 1. Kaplan-Meier Curve of PFS by IRC Assessment (ITT Analysis Set). Figure 1. Kaplan-Meier Curve of PFS by IRC Assessment (ITT Analysis Set). Figure 2. Forest Plot of Hazard Ratio for PFS by IRC Assessment (ITT Analysis Set). Figure 2. Forest Plot of Hazard Ratio for PFS by IRC Assessment (ITT Analysis Set). Conclusions: Idelalisib in combination with BR is superior to BR alone, reducing the risk of both PD and death, increasing PFS and OS, and with a safety profile consistent with prior reported studies. These results were consistent across pts with high-risk features. Addition of IDELA to BR was also beneficial in pts without del(17p)/TP53mut. This regimen represents an important new option for pts with R/R CLL. ClinicalTrials.gov ID: NCT01569295. Disclosures: Zelenetz: Gilead Sciences: Research Funding. Off Label Use: Idelalisib for relapsed/refractory CLL. Robak:MorphoSys AG: Consultancy , Honoraria , Research Funding ; Janssen: Consultancy , Research Funding ; Gilead Sciences: Research Funding. Coiffier:CELLTRION, Inc.: Consultancy , Honoraria ; Gilead Sciences: Research Funding. Delgado:Gilead Sciences: Research Funding. Marlton:Gilead Sciences: Research Funding. Adewoye:Gilead Sciences: Employment , Equity Ownership. Kim:Gilead Sciences: Employment , Equity Ownership. Dreiling:Gilead Sciences: Employment , Equity Ownership. Hillmen:Gilead Sciences: Honoraria , Research Funding ; Abbvie: Honoraria , Research Funding ; Janssen: Honoraria , Research Funding ; Roche: Honoraria , Research Funding ; Novartis: Honoraria , Research Funding ; Pharmacyclics: Honoraria , Research Funding ; Acerta Pharma BV: Research Funding.

Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5384-5384
Author(s):  
Victor H Jimenez-Zepeda ◽  
Christopher P. Venner ◽  
Andrew Belch ◽  
Irwindeep Sandhu ◽  
Tatiana Nikitina ◽  
...  
Keyword(s):  
High Risk ◽  
Research Funding ◽  
Plasma Cells ◽  
Progression Free Survival ◽  
Response Assessment ◽  
Median Number ◽  
Cancer Center ◽  
P Value ◽  
Weekly Schedule ◽  
Free Survival

Abstract Introduction: Pomalidomide is an IMiD that was recently approved for the use of relapsed MM failing lenalidomide and bortezomib. In the present study, we aimed to evaluate the efficacy of pomalidomide-containing regimens (PCR) for heavily-pretreated relapsed or refractory MM (RRMM) at Tom Baker Cancer Center and the Cross Cancer Institute in Alberta. Methods: We retrospectively reviewed the records of all patients with RRMM treated with PCR at our Institutions between 01/10 and 04/15. Patients received oral pomalidomide 2-4mg/d on days 1-21/28, and dexamethasone 20 mg or 40 mg on a weekly schedule, few cases were treated with PD in addition to bortezomib or cyclophosphamide. Definitions of response and progression were used according to the EBMT modified criteria. A p-value was considered statistically significant if <0.05 Results: Between 01/10 and 04/15, 90 patients were identified for the study. Clinical and laboratory characteristics are listed in Table 1. The median number of therapies prior to PCR was 3 (2-11). All patients received lenalidomide and bortezomib or another proteasome inhibitor prior to PCR; 47 patients had bortezomib, 31 had lenalidomide and 11 had both immediately prior to PCR. 21 patients out of 47 receiving bortezomib prior to PCR responded (44%) versus 32.2% (10/31), and 27.2% (3/11), for those receiving lenalidomide and lenalidomide/bortezomib, respectively prior to PCR (p=0.5). Four patients received pomalidomide at a dose of 2mg, 3 at 3mg and the rest at 4mg. After a median of 4 cycles, the ORR was 41.1%. The median time to first response was 8 weeks, with majority of cases achieving at least PR after 2 cycles. FISH cytogenetics at relapse, were available in 46 patients and 16 were high risk (HR, 34.8%). At a median follow-up of 8 months, 44% of patients were alive and 77.8% had already progressed. Median OS was 12.2 months and median PFS 4.0 months. Median PFS was 5.6 months in the group with standard risk (SR) disease compared to 2.9 months for the HR group (p=0.022). Median OS for SR patients was 19.4 months compared to 8 months for the HR group (p=0.11). Two patients discontinued therapy due to thrombocytopenia. Conclusion: Pomalidomide is an efficacious drug for the treatment of RRMM. The current report confirms the ORR seen in previous studies and suggests a trend to poorer outcomes for the HR cytogenetics group. Further assessment of combinations of pomalidomide with newer agents especially in the setting of HR cytogenetics are warranted. Table 1. Clinical Characteristics and Response assessment for patients with MM receiving pomalidomide-containing regimens Characteristic N=90 Age (median) 65 GenderMaleFemale 46 (51.1%)44 (48.9%) Hb (g/L) 108 (75-160) Calcium (µmol/L) 2.3 (1.98-3.28) Creatinine (µmol/L) 85.5 (60-1052) B2microglobulin (µmol/L) 3.96 (1.38-25.2) Albumin (g/L) 35.5 (11-52) Stage IStage IIStage III 15.9%52.3%31.8% LDH (IU/L) 190 (71-669) BMPC (%) 40% (5-90%) Heavy chain:IgGIgAIgDBiclonalIgMFLC onclyNon-secretory 61.1%20%01.1%5.6%10%2.2% Light chain:KappaLambda 64.4%33.3% Prior therapies:ASCTThalidomideLenalidomideBortezomibCarfilzomib 53.3%21.1%100%98.9%8.9% High risk (t(4;14), t(14;16), and p53 delStandard risk 34.8%65.2% Chemotherapy regimenDPPACEPomalidomide alonePomalidomide and DexamethasonePomalidomide/Bortezomib and DexamethasonePomalidomide and BortezomibPomalidomide, cyclophosphamide and prednisone 1.1%1.1%88.9%6.7%1.1%1.1% Response rateORRComplete Response/nCRVGPRPRSDMinimal ResponseProgression 41.1%2.2%5.6%33.3%18.9%10%30% Patients that have progressed 77.8% Patients that have died 55.6% BMPC: Bone marrow plasma cells; FLC: Free-light chains only; CC: Conventional cytogenetics Figure 1. Progression-Free survival according to high-risk cytogenetics by FISH Figure 1. Progression-Free survival according to high-risk cytogenetics by FISH Disclosures Jimenez-Zepeda: J&J: Honoraria; Celgene: Honoraria; Amgen: Honoraria. Venner:Amgen: Honoraria; J&J: Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Sandhu:Novartis: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. Duggan:Jansen: Honoraria; Celgene: Honoraria. Neri:Celgene: Research Funding. Bahlis:Johnson & Johnson: Research Funding; Amgen: Consultancy; Johnson & Johnson: Consultancy; Johnson & Johnson: Speakers Bureau; Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau.

scholarly journals Health research funding and its output in Pakistan

2021 ◽  
Author(s):  
Muhammad A.N. Saqib ◽  
Ibrar Rafique
Keyword(s):  
Health Research ◽  
Research Funding ◽  
Gradual Increase ◽  
Research Output ◽  
Evidence Based ◽  
Education Commission ◽  
Health Research Council ◽  
International Donors ◽  
Number Of Publications ◽  
Local Agencies

Background: Health research is very important for formulating evidence-based policies. Aims: To assess the health research funding and its output in the last 5 fiscal years (2013–14 to 2018) in Pakistan. Methods: Information about health research funding was retrieved from 3 major local agencies, the Higher Education Commission, the Pakistan Science Foundation and the Pakistan Health Research Council. Details of funding from international donors were retrieved and the number of publications was estimated from Pubmed and Pakmedinet. Results: A total of 1261.6 million Pakistan rupees (Rs) (US$ 8.4 million) was spent on health research in the last 5 fiscal years, the majority from local donors (P < 0.02). Overall funding increased from Rs 104.7 million in 2013–14 to Rs 349.8 million 2017–18. In publications data, 24 796 original articles were published, including 16 137 Medline and 8659 non-Medline indexed. Overall there was a gradual increase in the number of publications per year, statistically significant for Medline indexed journals. Research funding had a strong correlation (Cronbach α 0.88) with publications. Conclusion: Health research funding directly affects health research output. The funding on health research should be considered an investment rather than expenditure.

scholarly journals AB0132 THE STUDY OF SUBCLINICAL SYNOVITIS DETECTED BY ULTRASONOGRAPHY AND MRI IN RA PATIENTS AFTER REACHING CLINICAL REMISSION ON PATIENT’S SUBJECTIVE SYMPTOMS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1094.2-1094
Author(s):  
M. Nawata ◽  
K. Someya ◽  
T. Aritomi ◽  
M. Funada ◽  
K. Nakamura ◽  
...  
Keyword(s):  
Clinical Remission ◽  
Research Funding ◽  
Morning Stiffness ◽  
Univariate Analysis ◽  
P Value ◽  
Research Support ◽  
Residual Symptoms ◽  
Logistic Analysis ◽  
Significant Difference ◽  
Multivariate Logistic Analysis

Background:The goal of treatment in rheumatoid arthritis (RA) is to achieve remission. There is the patient with residual symptoms in the Japanese RA patient who achieved clinical remission. There are not many studies to examine the relation between everyday life, social activity and evaluation of disease activities using high-sensitivity image examinations (musculoskeletal ultrasound (MSKUS) and MRI).Objectives:To examine the relationship between subjective residual symptoms and imaging examinations in RA patients who have achieved clinical remission.Methods:30 RA patients who achieved SDAI remission during RA treatment. Age, sex, disease duration, physical findings, serological markers, disease activity, HAQ, EQ-5D-5L, FACIT-F, Patient Reported Outcomes (PROs), EGA and medications were evaluated. 44 joints were assessed by MSKUS with gray scale (GS) and power doppler (PD) and contrast-enhanced bilateral joint MRI scoring with OMERACT-RAMRIS scoring.Results:1. The mean SDAI of the 30 RA patients was 1.3. 2.In the analysis of the presence or absence of subjective residual symptoms that led to remission of SDAI (Table 1).Table 1.Subjective residual symptoms/presence (N=17)Subjective residual symptoms/absence (N=13)Univariate analysisp valueMultivariate logistic analysisp valueTJC0.0±0.00.3±0.50.0173HAQ0.4±0.40.05±0.10.00950.00181EQ5D-5L0.8±0.10.9±0.00.0001FACIT-F14.5±9.84.6±4.30.0233Morning stiffness (min)256.5±564.80.0±0.00.0210Pain (VAS) (mm)9.2±9.50.9±1.50.00440.0455PGA (mm)7.7±9.00.5±1.10.0013(1). In the univariate analysis, the number of tender joints, HAQ, EQ-5D-5L, FACIT-F, morning stiffness, and pain VAS were extracted with significant differences.(2). In multivariate logistic analysis, HAQ and pain VAS were extracted as independent factors with significant differences. 3.In univariate analysis of the association between HAQ and pain VAS extracted in multivariate logistic analysis and imaging examinations (MSKUS/MRI), MRI-synovitis was extracted with a significant difference in HAQ.Conclusion:1. It was suggested that Pain VAS and HAQ due to RA could be identified in patients reaching SDAI remission. 2. In patients reaching SDAI remission, Pain VAS ≤10 or HAQ ≤0.5 suggested that subjective residual symptoms may be eliminated. 3. HAQ ≤ 0.5 suggests that synovitis is less likely to be detected on MRI. 4. In patients who have reached SDAI remission, little residual inflammation was observed on US, suggesting that induction of remission is important not only to prevent joint destruction, but also to improve and maintain long-term QoL.Disclosure of Interests:MASAO NAWATA Grant/research support from: I have received research funding from Eli Lilly Japan K.K., Kazuki Someya: None declared, Takafumi Aritomi: None declared, Masashi funada: None declared, Katsumi Nakamura: None declared, SAITO KAZUYOSHI Grant/research support from: I have received research funding from Eli Lilly Japan K.K., Yoshiya Tanaka Speakers bureau: I have received speaking fees from Abbvie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-Myers, Astellas, Eisai, Janssen, Pfizer, Asahi-kasei, Eli Lilly, GlaxoSmithKline, UCB, Teijin, MSD, and Santen, Consultant of: I have received consulting fees from Abbvie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-Myers, Astellas, Eisai, Janssen, Pfizer, Asahi-kasei, Eli Lilly, GlaxoSmithKline, UCB, Teijin, MSD, and Santen, Grant/research support from: I have received research grants from Mitsubishi-Tanabe, Takeda, Chugai, Astellas, Eisai, Taisho-Toyama, Kyowa-Kirin, Abbvie, and Bristol-Myers

scholarly journals Authorship inequality: a bibliometric study of the concentration of authorship among a diminishing number of individuals in high-impact medical journals, 2008–2019

BMJ Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. e046002
Author(s):  
Kamber L Hart ◽  
Roy H Perlis
Keyword(s):  
Research Funding ◽  
High Impact ◽  
High Impact Journal ◽  
Medical Journals ◽  
Medical Specialties ◽  
Academic Medical ◽  
Rate Of Increase ◽  
Number Of Publications ◽  
Author Position ◽  
Number Of Individuals

ObjectiveAuthorship and number of publications are important criteria used for making decisions about promotions and research funding awards. Given the increase in the number of author positions over the last few decades, this study sought to determine if there had been a shift in the distribution of authorship among those publishing in high-impact academic medical journals over the last 12 years.DesignThis study analysed the distribution of authorship across 312 222 original articles published in 134 medium-impact to high-impact academic medical journals between 1 January 2008 and 31 December 2019. Additionally, this study compared the trends in author distributions across nine medical specialties and a collection of cross-specialty high-impact journal articles.Primary outcome measuresThe distribution of authorship was assessed using the Gini coefficient (GC), a widely used measure of economic inequality.ResultsThe overall GC for all articles sampled across the 12-year study period was 0.49, and the GCs for the first and last authorship positions were 0.30 and 0.44, respectively. Since 2008, there was a significant positive correlation between year and GC for the overall authorship position (r=0.99, p<0.001) the first author position (r=0.75, p=0.007) and the last author position (r=0.85, p<0.001) indicating increasingly uneven distribution in authorship over time. The cross-specialty high-impact journals exhibited the greatest rate of increase in GC over the study period for the first and last author position of any specialty analysed.ConclusionOverall, these data suggest a growing inequality in authorship across authors publishing in high-impact academic medical journals, especially among the highest impact journals. These findings may have implications for processes such as promotions and allocation of research funding that use authorship metrics as key criteria for making decisions.

scholarly journals Current Priorities in Health Research Funding and Lack of Impact on the Number of Child Deaths per Year

2007 ◽  
Vol 97 (2) ◽  
pp. 219-223 ◽  
Author(s):  
Jef L. Leroy ◽  
Jean-Pierre Habicht ◽  
Gretel Pelto ◽  
Stefano M. Bertozzi
Keyword(s):  
Health Research ◽  
Research Funding ◽  
Child Deaths
Sign in / Sign up

Export Citation Format

Share Document